Phase 1b/2a Safety and Tolerability of SYN-004 in Allo-HCT Subjects
Condition: 121121000119106, Reduction of the Incidence and/or Severity of Acute Graft-versus-host Reaction Following Bone Marrow Transplant (Disorder) Intervention: Biological: SYN-004, Ribaxamase or Placebo Sponsors: Synthetic Biologics Inc.; Washington University School of Medicine Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials